Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Express Scripts
AstraZeneca
Harvard Business School
Mallinckrodt

Last Updated: May 27, 2022

Metuchen Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for METUCHEN PHARMS, and what generic alternatives to METUCHEN PHARMS drugs are available?

METUCHEN PHARMS has one approved drug.

There are two US patents protecting METUCHEN PHARMS drugs.

There are fifty-three patent family members on METUCHEN PHARMS drugs in twenty-six countries and eleven supplementary protection certificates in eleven countries.

Summary for Metuchen Pharms
International Patents:53
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Metuchen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No 6,656,935 See Plans and Pricing Y Y See Plans and Pricing
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No 7,501,409 See Plans and Pricing Y See Plans and Pricing
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes 6,656,935 See Plans and Pricing Y Y See Plans and Pricing
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No 6,656,935 See Plans and Pricing Y Y See Plans and Pricing
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No 7,501,409 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-04-27

Supplementary Protection Certificates for Metuchen Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1219609 C300618 Netherlands See Plans and Pricing PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
1219609 C01219609/01 Switzerland See Plans and Pricing PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: SWISSMEDIC 65275 22.01.2016
1219609 122013000096 Germany See Plans and Pricing PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621
1219609 CA 2013 00040 Denmark See Plans and Pricing
1219609 SPC/GB13/071 United Kingdom See Plans and Pricing PRODUCT NAME: AVANAFIL; REGISTERED: UK EU/1/13/841 20130621
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
Harvard Business School
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.